Systemically delivered insulin-like growth factor-I enhances mesenchymal stem cell-dependent fracture healing

References

• Ai-Aql ZS, Alagl AS, Graves DT, Gerstenfeld LC, Einhorn TA. 2008. Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis. J Dent Res. 87:107–118.
   PubMed Web of Science ®Google Scholar
• Axelrad TW, Kakar S, Einhorn TA. 2007. New technologies for the enhancement of skeletal repair. Injury. 38 Suppl. 1: S49–S62.
   PubMedGoogle Scholar
• Bielby R, Jones E, McGonagle D. 2007. The role of mesenchymal stem cells in maintenance and repair of bone. Injury. 38 Suppl. 1: S26–S32.
   PubMedGoogle Scholar
• Boonen S, Rosen C, Bouillon R, Sommer A, McKay M, Rosen D, Adams S, Broos P, Lenaerts J, Raus J, Vanderschueren D, Geusens P. 2002. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: A double-blind, placebo-controlled pilot study. J Clin Endocrinol Metab. 87:1593–1599.
   PubMed Web of Science ®Google Scholar
• Caplan AI. 2007. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol. 213:341–347.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Ho H, Song F, LI A, Santa Maria C, Wang Y, You M, Tu C, Bikle D, Chang W. Presented at the The American Society of Bone Mineral Research 2011 Annual Meeting, San Diego, CA, September 16–20 2011..
   Google Scholar
• Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE. 2007. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab. 92:902–910.
   PubMed Web of Science ®Google Scholar
• Clemens TL, Chernausek SD. 2004. Genetic strategies for elucidating insulin-like growth factor action in bone. Growth Hormone IGF Res Off J Growth Hormone Res Soc Int IGF Res Soc. 14:195–199.
   PubMed Web of Science ®Google Scholar
• Colnot C. 2009. Skeletal cell fate decisions within periosteum and bone marrow during bone regeneration. J Bone Miner Res Off J Am Soc Bone Miner Res. 24:274–282.
   PubMed Web of Science ®Google Scholar
• Conover CA. 2000. In vitro studies of insulin-like growth factor I and bone. Growth Hormone IGF Res Off J Growth Hormone Res Soc Int IGF Res Soc. 10 Suppl. B: S107–S110.
   PubMedGoogle Scholar
• da Silva Meirelles L, Caplan AI, Nardi NB. 2008. In search of the in vivo identity of mesenchymal stem cells. Stem Cells. 26:2287–2299.
   PubMed Web of Science ®Google Scholar
• De Bari C, Dell'Accio F, Vandenabeele F, Vermeesch JR, Raymackers JM, Luyten FP. 2003. Skeletal muscle repair by adult human mesenchymal stem cells from synovial membrane. J Cell Biol. 160:909–918.
   PubMed Web of Science ®Google Scholar
• De Bari C, Dell'Accio F, Vanlauwe J, Eyckmans J, Khan IM, Archer CW, Jones EA, McGonagle D, Mitsiadis TA, Pitzalis C, Luyten FP. 2006. Mesenchymal multipotency of adult human periosteal cells demonstrated by single-cell lineage analysis. Arthritis Rheumatism. 54:1209–1221.
   PubMed Web of Science ®Google Scholar
• Deal KK, Cantrell VA, Chandler RL, Saunders TL, Mortlock DP, Southard-Smith EM. 2006. Distant regulatory elements in a Sox10-beta GEO BAC transgene are required for expression of Sox10 in the enteric nervous system and other neural crest-derived tissues. Dev Dyn. 235:1413–1432.
   PubMedGoogle Scholar
• Di Monaco M, Vallero F, Di Monaco R, Tappero R, Cavanna A. 2009. Serum levels of insulin-like growth factor-I are positively associated with functional outcome after hip fracture in elderly women. Am J Phys Med Rehabil. 88:119–125.
   PubMedGoogle Scholar
• Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. International Society for Cellular Therapy position statement. Cytotherapy. 8:315–317.
   PubMed Web of Science ®Google Scholar
• Einhorn TA. 1995. Enhancement of fracture-healing. J Bone Joint Surg Am. 77:940–956.
   PubMed Web of Science ®Google Scholar
• Fowlkes JL, Thrailkill KM, Liu L, Wahl EC, Bunn RC, Cockrell GE, Perrien DS, Aronson J, Lumpkin CKJr. 2006. Effects of systemic and local administration of recombinant human IGF-I (rhIGF-I) on de novo bone formation in an aged mouse model. J Bone Miner Res Off J Am Soc Bone Miner Res. 21:1359–1366.
   PubMedGoogle Scholar
• Gerstenfeld LC, Cullinane DM, Barnes GL, Graves DT, Einhorn TA. 2003. Fracture healing as a post-natal developmental process: Molecular, spatial, and temporal aspects of its regulation. J Cell Biochem. 88:873–884.
   PubMed Web of Science ®Google Scholar
• Gerstenfeld LC, Wronski TJ, Hollinger JO, Einhorn TA. 2005. Application of histomorphometric methods to the study of bone repair. J Bone Miner Res Off J Am Soc Bone Miner Res. 20:1715–1722.
   PubMed Web of Science ®Google Scholar
• Giordano A, Galderisi U, Marino IR. 2007. From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells. J Cell Physiol. 211:27–35.
   PubMed Web of Science ®Google Scholar
• Granero-Molto F, Myers TJ, Weis JA, Longobardi L, Li T, Yan Y, Case N, Rubin J, Spagnoli A. 2011. Mesenchymal stem cells expressing insulin-like growth factor-I (MSC(IGF)) promote fracture healing and restore new bone formation in Irs1 knockout mice: Analyses of MSC(IGF) autocrine and paracrine regenerative effects. Stem Cells. 29:1537–1548.
   PubMed Web of Science ®Google Scholar
• Granero-Molto F, Weis JA, Longobardi L, Spagnoli A. 2008. Role of mesenchymal stem cells in regenerative medicine: Application to bone and cartilage repair. Expert Opin Biol Ther. 8:255–268.
   PubMed Web of Science ®Google Scholar
• Granero-Molto F, Weis JA, Miga MI, Landis B, Myers TJ, O'Rear L, Longobardi L, Jansen ED, Mortlock DP, Spagnoli A. 2009. Regenerative effects of transplanted mesenchymal stem cells in fracture healing. Stem Cells. 27:1887–1898.
   PubMed Web of Science ®Google Scholar
• Guler HP, Zapf J, Froesch R. 1987. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med. 317:137–140.
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC, Martinache C, Rieux-Laucat F, Latour S, Belohradsky BH, Leiva L, Sorensen R, Debre M, Casanova JL, Blanche S, Durandy A, Bushman FD, Fischer A, Cavazzana-Calvo M. 2010. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 363:355–364.
   PubMed Web of Science ®Google Scholar
• Hernigou P, Poignard A, Beaujean F, Rouard H. 2005. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am. 87:1430–1437.
   PubMed Web of Science ®Google Scholar
• Kanakaris NK, Paliobeis C, Nlanidakis N, Giannoudis PV. 2007. Biological enhancement of tibial diaphyseal aseptic non-unions: The efficacy of autologous bone grafting, BMPs and reaming by-products. Injury. 38 Suppl. 2: S65–S75.
   PubMedGoogle Scholar
• Kerr D, Tamborlane WV, Rife F, Sherwin RS. 1993. Effect of insulin-like growth factor-1 on the responses to and recognition of hypoglycemia in humans. A comparison with insulin. J Clin Invest. 91:141–147.
   PubMed Web of Science ®Google Scholar
• Klinger B, Laron Z. 1995. Three year IGF-I treatment of children with Laron syndrome. J Pediatric Endocrinol Metab JPEM. 8:149–158.
   Google Scholar
• Langlois JA, Rosen CJ, Visser M, Hannan MT, Harris T, Wilson PW, Kiel DP. 1998. Association between insulin-like growth factor I and bone mineral density in older women and men: The Framingham heart study. J Clin Endocrinol Metab. 83:4257–4262.
   PubMed Web of Science ®Google Scholar
• Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P, Prockop DJ. 2009. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 5:54–63.
   PubMed Web of Science ®Google Scholar
• Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. 1993. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell. 75:59–72.
   PubMed Web of Science ®Google Scholar
• Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A. 2001. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol. 229:141–162.
   PubMed Web of Science ®Google Scholar
• Mahendra A, Maclean AD. 2007. Available biological treatments for complex non-unions. Injury. 38 Suppl. 4: S7–S12.
   PubMedGoogle Scholar
• Marsh D. 1998. Concepts of fracture union, delayed union, and nonunion. Clin Orthopaedics Relat Res. 355s:S22–S30.
   Google Scholar
• Myers TJ, Granero-Molto F, Longobardi L, Li T, Yan Y, Spagnoli A. 2010. Mesenchymal stem cells at the intersection of cell and gene therapy. Expert Opin Biol Ther. 10:1663–1679.
   PubMed Web of Science ®Google Scholar
• Nakasaki M, Yoshioka K, Miyamoto Y, Sasaki T, Yoshikawa H, Itoh K. 2008. IGF-I secreted by osteoblasts acts as a potent chemotactic factor for osteoblasts. Bone. 43:869–879.
   PubMed Web of Science ®Google Scholar
• Nauta AJ, Fibbe WE. 2007. Immunomodulatory properties of mesenchymal stromal cells. Blood. 110:3499–3506.
   PubMed Web of Science ®Google Scholar
• Pittenger M. 2009. Sleuthing the source of regeneration by MSCs. Cell Stem Cell. 5:8–10.
   PubMedGoogle Scholar
• Powell-Braxton L, Hollingshead P, Warburton C, Dowd M, Pitts-Meek S, Dalton D, Gillett N, Stewart TA. 1993. IGF-I is required for normal embryonic growth in mice. Genes Dev. 7:2609–2617.
   PubMed Web of Science ®Google Scholar
• Praemer A, Furner S, Rice DP. 1999. Musculoskeletal conditions in the United States. Park Ridge, IL: The American Academy of Orthopaedic Surgeons.
   Google Scholar
• Prockop DJ. 1997. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 276:71–74.
   PubMed Web of Science ®Google Scholar
• Prockop DJ. 2009. Repair of tissues by adult stem/progenitor cells (MSCs): Controversies, myths, and changing paradigms. Mol Ther. 17:939–946.
   PubMed Web of Science ®Google Scholar
• Prockop DJ, Olson SD. 2007. Clinical trials with adult stem/progenitor cells for tissue repair: Let's not overlook some essential precautions. Blood. 109:3147–3151.
   PubMed Web of Science ®Google Scholar
• Raschke M, Wildemann B, Inden P, Bail H, Flyvbjerg A, Hoffmann J, Haas NP, Schmidmaier G. 2002. Insulin-like growth factor-1 and transforming growth factor-beta1 accelerates osteotomy healing using polylactide-coated implants as a delivery system: A biomechanical and histological study in minipigs. Bone. 30:144–151.
   PubMed Web of Science ®Google Scholar
• Reynolds DG, Hock C, Shaikh S, Jacobson J, Zhang X, Rubery PT, Beck CA, O'Keefe RJ, Lerner AL, Schwarz EM, Awad HA. 2007. Micro-computed tomography prediction of biomechanical strength in murine structural bone grafts. J Miomech. 40:3178–3186.
   Google Scholar
• Rosen CJ, Dimai HP, Vereault D, Donahue LR, Beamer WG, Farley J, Linkhart S, Linkhart T, Mohan S, Baylink J. 1997. Circulating and skeletal insulin-like growth factor-I (IGF-I) concentrations in two inbred strains of mice with different bone mineral densities. Bone. 21:217–223.
   PubMed Web of Science ®Google Scholar
• Sasaki M, Abe R, Fujita Y, Ando S, Inokuma D, Shimizu H. 2008. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J Immunol. 180:2581–2587.
   PubMed Web of Science ®Google Scholar
• Schmidmaier G, Wildemann B, Heeger J, Gabelein T, Flyvbjerg A, Bail HJ, Raschke M. 2002. Improvement of fracture healing by systemic administration of growth hormone and local application of insulin-like growth factor-1 and transforming growth factor-beta1. Bone. 31:165–172.
   PubMed Web of Science ®Google Scholar
• Spagnoli A, Longobardi L, O'Rear L. 2005. Cartilage disorders: Potential therapeutic use of mesenchymal stem cells. Endocrine Dev. 9:17–30.
   PubMedGoogle Scholar
• Trippel SB. 1998. Potential role of insulinlike growth factors in fracture healing. Clin Orthopaedics Relat Res. 355s:S301–S313.
   Google Scholar
• Uccelli A, Moretta L, Pistoia V. 2008. Mesenchymal stem cells in health and disease. Nature reviews. Immunology. 8:726–736.
   PubMedGoogle Scholar
• Wang Y, Nishida S, Sakata T, Elalieh HZ, Chang W, Halloran BP, Doty SB, Bikle DD. 2006. Insulin-like growth factor-I is essential for embryonic bone development. Endocrinology. 147:4753–4761.
   PubMedGoogle Scholar
• Weis JA, Miga MI, Granero-Molto F, Spagnoli A. 2010. A finite element inverse analysis to assess functional improvement during the fracture healing process. J Biomech. 43:557–562.
   PubMedGoogle Scholar
• Yakar S, Canalis E, Sun H, Mejia W, Kawashima Y, Nasser P, Courtland HW, Williams V, Bouxsein M, Rosen C, Jepsen KJ. 2009. Serum IGF-1 determines skeletal strength by regulating subperiosteal expansion and trait interactions. J Bone Miner Res Off J Am Soc Bone Miner Res. 24:1481–1492.
   PubMed Web of Science ®Google Scholar
• Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D. 2002. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 110:771–781.
   PubMed Web of Science ®Google Scholar
• Zhao G, Monier-Faugere MC, Langub MC, Geng Z, Nakayama T, Pike JW, Chernausek SD, Rosen CJ, Donahue LR, Malluche HH, Fagin JA, Clemens TL. 2000. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: Increased trabecular bone volume without increased osteoblast proliferation. Endocrinology. 141:2674–2682.
   PubMed Web of Science ®Google Scholar